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Introduction
Medication overuse headache (MOH) is a major clinical
problem in most Western countries [1–5]. MOH has been
recently introduced in the International Classification of
Headache Disorders [2]. The overuse of acute medications
in patients who are suffering from headache represents a
great challenge to headache management. MOH repre-
sents one of the most common iatrogenic disorders and
possibly shares some pathogenetic mechanisms with other
kinds of drug addiction. The recent development of acute
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headache (MOH) is a clinically
important entity and it is now well
documented that the regular use of
acute symptomatic medication by
people with migraine or tension-
type headache increases the risk of
aggravation of the primary
headache. MOH is one of the most
common causes of chronic
migraine-like syndrome. Because of
easy availability and low expense,
the greatest problem appears to be
associated with barbiturate-contain-
ing combination analgesics and
over-the-counter caffeine-contain-
ing combination analgesics. Even
though triptan overuse headache is
not encountered with great frequen-
cy, all triptans should be considered
potential inducers of MOH. There
are several different theories
regarding the aetiology of MOH,
including: (i) central sensitisation
from repetitive activation of noci-
ceptive pathways; (ii) a direct effect
of the medication on the capacity of
the brain to inhibit pain; (iii) a
decrease in blood serotonin due to
repetitive medication administration
with alteration of serotonin recep-
tors; (iv) cellular adaptation in the
brain; and (v) changes in the peri-
aqueductal grey matter. The princi-
pal approach to management of
MOH is built around cessation of
overused medication. Without dis-
continuation of the offending med-
ication, improvement is almost
impossible to attain. Thus, the best
management advice is to raise
awareness and strive for prevention.
In this article, we analyse also the
possible mechanisms that underlie
sensitisation in MOH by comparing
these mechanisms with those
reported for other forms of drug
addiction.
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headache medications, especially the triptans, provided
increased migraine relief. Nevertheless, the emergence of
triptan overuse headache has also gained interest.
Similarly, others symptomatic drugs for headache relief
such as ergots, analgesics, opioids, morphinomimetics and
barbiturates can cause MOH [1–5].
MOH is an interaction between a therapeutic agent
used excessively and a susceptible patient. Awareness of
MOH and familiarity with the diagnosis and treatment of
this disorder are important to physicians who treat patients
with headache. Features of migraine and tension-type
headache often coexist in MOH. The diagnosis of MOH is
clinically extremely important because patients rarely
respond to prophylactic medications whilst overusing
acute medications [6]. Furthermore, the understanding of
the pathophysiological mechanisms underlying MOH may
help to explore appropriate therapeutical strategies. The
general term of MOH encompasses those headaches pre-
senting more than 15 days per month [2].
Patients suffering from MOH represent a great number
of patients referring to headache specialistic centres.
Moreover, these patients have high frequencies of psychi-
atric comorbidity or psychologic distress in clinic-based
studies [7]. The presence of psychologic distress con-
tributes to poor quality of life in patients with MOH.
Overuse of various compounds frequently leads to a
state of dependency. This kind of headache can be caused
by the intake of combination analgesics, opioids, ergot
alkaloids, aspirin, non-steroidal anti-inflammatory drugs,
caffeine and triptans [1–6].
The most frequent cause for the transformation of a
periodic headache into a chronic disabling headache is
substance abuse. Substance abuse and drug dependency
have multiple causes, and the aetiology resides with the
compounds that are used to excess.
The problem may arise as a result of poor instructions
from the physician, improper diagnosis with gradual esca-
lation in amounts of drug consumed, or a reinforcement
mechanism and a brain stimulation-reward effect.
Frequent use (≥15 times/month) of medication for the
treatment of acute migraine attacks may cause MOH. The
delay between first intake and daily headache is shortest
for triptans (1–2 years), longer for ergots (3 years) and
longest for analgesics (5 years) [1].
Analgesic and ergot alkaloid combinations with caffeine
often lead to a relapse. However, patients overusing opioids
have the highest relapse rate after withdrawal treatment.
Some studies have suggested that triptan overuse may
increase migraine frequency to that of chronic migraine.
Evidence suggests that this occurs sooner with triptan
overuse than with ergotamine overuse.
Complete withdrawal from headache medication is the
treatment of choice for MOH. Discontinuation of the
overused headache medication, however, results in the
development of withdrawal headache, often associated
with nausea, vomiting and sleep disturbances [1–6].
Drug-induced sensitisation and MOH
Sensitisation is the enhanced response to a stimulus that
occurs with repeated exposure to that stimulus.
Psychostimulants are perhaps the best-studied drugs of
abuse in terms of producing sensitisation. Behavioural
sensitisation is the augmented motor-stimulant response
that occurs with repeated, intermittent exposure to cocaine
and amphetamine. Sensitisation is hypothesised to under-
lie the craving associated with drug abuse that may lead to
relapse following a period of abstinence. In addition,
cross-sensitisation occurs between drugs of abuse, sug-
gesting that common mechanisms may underlie the devel-
opment of sensitisation to drugs targeting different neuro-
transmitters [8, 9].
Certain features of MOH, namely, increased headache
frequency, expansion of headache area and cutaneous
allodynia, may imply sensitisation of central nociceptive
neurons in the trigeminal pathway as well as in cells of the
periaqueductal grey (PAG).
Repetitive activation of the trigeminal nerve can lead
to a biologic and functional change in trigeminal nucleus
caudalis neurons, characterised by a decrease in nocicep-
tive threshold and receptive field expansion. Suppression
of the endogenous pain control system can facilitate the
process of central sensitisation [10]. A similar process
might be also involved in the sensitisation induced by
medication overuse in tension-type headache patients [8].
Sensitisation underlies the craving associated to drug
abuse leading to relapse following a period of abstinence.
In support of this hypothesis, sensitisation may last
months to years following the cessation of drug exposure.
Whether sensitisation may occur as a consequence of
medication overuse in headache patients or it is caused by
the repetitive occurrence of episodes of stressful events
such as headache episodes is still unclear [11].
Nevertheless, behavioural correlates associated with
MOH might partially resemble some of the more charac-
teristic features of the behavioural sensitisation to psy-
chostimulants. Among these features the most important
are the requirement of repeated administrations during a
certain period of time, the tendency to have a “craving” in
the early phase of abstinence, and the occurrence of cross-
sensitisation among different drugs used to treat
headache. In addition, the tendency to reach a status in
which the assumption of the drugs is induced by a “com-
pulsive” and stereotypical behaviour rather than by real
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medical needs, and the possibility to observe a relapse
after relatively long periods of abstinence may resemble
the characteristics of drug addiction [12].
The first step among the several biochemical changes
required to induce synaptic plasticity and central sensiti-
sation is an increased extracellular level of glutamate [8,
13]. A significant increase in glutamate levels has been
detected in the cerebrospinal fluid of patients with chron-
ic forms of headache [8].
Central sensitisation and storage of information at a
cellular level also require changes at maintained tran-
scriptional level. Several different intracellular signal
transduction cascades converge on mitogen-activated pro-
tein kinase (MAPK), activation of which appears to be a
master switch or gate for the regulation of central sensiti-
sation via transcriptional regulation of key gene products.
Thus, memory traces of painful events can be retained as
a form of long-term increase in the efficacy of excitatory
synaptic transmission [8, 10, 11].
Are MOH patients sharing an obsessive-compulsive pro-
file with other addictions?
Psychiatric comorbidity, especially major depression,
anxiety and panic disorders, has been found to be highly
prevalent in patients with chronic headache and MOH [7,
14]. Comparing psychiatric comorbidity between
migraineurs with and without chronic drug overuse a sig-
nificantly higher prevalence of major depressive disorder,
panic disorder and social phobia has been found in the
patients with a history of chronic substance use.
Drug dependence disorders have been found to be
associated with various comorbid psychiatric disorders
including panic attacks, social phobia, specific phobia and
obsessive-compulsive disorder (OCD) [15, 16].
Although neuropsychological and neuroimaging stud-
ies of OCD have implicated cortical areas, subcortical
structures (i.e., the ventral and dorsal striatum) seem also
to play a major role in the pathophysiology of the disor-
der. Accordingly, neuropsychological studies have
demonstrated that patients with OCD showed specific
cognitive deficits on tasks of executive and visual memo-
ry function [8, 15, 16].
Patients with chronic headaches and MOH bear simi-
larities to drug or substance abuse patients, for whom
genetic liability loci have been implicated. Molecular
genetic studies in this field are, however, still few and
preliminary.
Shared neurobiological features characterise substance
use disorders and other compulsive behaviours (alco-
holism, pathological gambling, compulsive shopping,
compulsive sexual behaviours, compulsive computer use).
Thus, future clinical and genetic studies on the comorbid-
ity between MOH patients, other forms of addiction and
OCD are needed.
The common pathogenetic role of 5-HT in both MOH
and OCD can establish an additional link between these
two disorders. Moreover, it is worth noting that selective
serotonin reuptake inhibitors (SSRI) are effective in the
treatment of OCD but they may also represent a therapeu-
tic option in MOH [8].
Conclusions
In recent years, advances in brain research have resulted
in a striking strategic shift in studies designed to develop
new, effective treatments for MOH as well as for related
neuropsychiatric disorders. This involves a multidiscipli-
nary approach with recursive interactions among respec-
tive disciplines with the ultimate goal of contributing to
treatment development. New common perspectives for
treatment of MOH, drug abuse and other related psychi-
atric disorders may arise from brain imaging and molec-
ular and pharmacogenetic studies, showing a shared
pathophysiological base among these disorders.
Translational components of this research include the
potential for integrating advances in brain imaging and
molecular and pharmacogenetic assessments as they may
potentially relate to neurodiagnostic assessment and
treatment development.
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